REPL earnings date and last-quarter result: last quarter miss, P/E -3.18. Updated 2026-07-23.
Replimune Group (REPL) Research Hub
Replimune Group (REPL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12.47 USD (+8.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.18, market cap 0.92B. This hub links to the full technical, earnings and options research available for REPL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.47 USD (+8.81%) |
| 52-week range | 4.76 USD – 16.02 USD |
| Trend regime | Range |
| 14-day RSI | 44 (Bearish) |
| Trailing P/E | -3.18 |
| Market cap | 0.92B |
| Dividend yield | 0.00% |
Available research for REPL
Covered Call on REPL: how it works, illustrative setup around the real 12.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on REPL: how it works, illustrative setup around the real 12.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on REPL: how it works, illustrative setup around the real 12.47 USD price, max profit/loss, breakeven and when to use it. Educational.
REPL technical analysis: range, last 12.47 USD, RSI 44, 52w range 4.76 USD–16.02 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is REPL in?
Replimune Group (REPL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is REPL in an uptrend or downtrend?
As of 2026-10-26, REPL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is REPL's trailing P/E ratio?
REPL's trailing P/E is -3.18, with a market cap of 0.92B. See the earnings research page for full valuation detail.